Literature DB >> 11284724

Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.

G P Hayhurst1, J Harlow, J Chowdry, E Gross, E Hilton, M S Lennard, G T Tucker, S W Ellis.   

Abstract

Homology models of the active site of cytochrome P450 2D6 (CYP2D6) have identified phenylalanine 481 (Phe(481)) as a putative ligand-binding residue, its aromatic side chain being potentially capable of participating in pi-pi interactions with the benzene ring of ligands. We have tested this hypothesis by replacing Phe(481) with tyrosine (Phe(481)-->Tyr), a conservative substitution, and with leucine (Phe(481)-->Leu) or glycine (Phe(481)-->Gly), two non-aromatic residues, and have compared the properties of the wild-type and mutant enzymes in microsomes prepared from yeast cells expressing the appropriate cDNA-derived protein. The Phe(481)-->Tyr substitution did not alter the kinetics [K(m) (microM) and V(max) (pmol/min per pmol) respectively] of oxidation of S-metoprolol (27; 4.60), debrisoquine (46; 2.46) or dextromethorphan (2; 8.43) relative to the respective wild-type values [S-metoprolol (26; 3.48), debrisoquine (51; 3.20) and dextromethorphan (2; 8.16)]. The binding capacities [K(s) (microM)] of a range of CYP2D6 ligands to the Phe(481)-->Tyr enzyme (S-metoprolol, 22.8; debrisoquine, 12.5; dextromethorphan, 2.3; quinidine, 0.13) were also similar to those for the wild-type enzyme (S-metoprolol, 10.9; debrisoquine, 8.9; dextromethorphan, 3.1; quinidine, 0.10). In contrast, the Phe(481)-->Leu and Phe(481)-->Gly substitutions increased significantly (3-16-fold) the K(m) values of oxidation of the three substrates [S-metoprolol (120-124 microM), debrisoquine (152-184 microM) and dextromethorphan (20-31 microM)]. Similarly, the K(s) values of the ligands to Phe(481)-->Leu and Phe(481)-->Gly mutants were also increased 3 to 10-fold (S-metoprolol, 33.2-41.9 microM; debrisoquine, 85-90 microM; dextromethorphan, 15.7-18.8 microM; quinidine 0.35-0.53 microM). However, contrary to a recent proposal that Phe(481) has the dominant role in the binding of substrates that undergo CYP2D6-mediated N-dealkylation routes of metabolism, the Phe(481)-->Gly substitution did not substantially decrease the capacity of the enzyme to N-deisopropylate metoprolol (wild-type, 1.12 pmol/min per pmol of P450; Phe(481)-->Gly, 0.71), whereas an Asp(301)-->Gly substitution decreased the N-dealkylation reaction by 95% of the wild-type rate. Overall, our results are consistent with the proposal that Phe(481) is a ligand-binding residue in the active site of CYP2D6 and that the residue interacts with ligands via a pi-pi interaction between its phenyl ring and the aromatic moiety of the ligand. However, the relative importance of Phe(481) in binding is ligand-dependent; furthermore, its importance is secondary to that of Asp(301). Finally, contrary to predictions of a recent homology model, Phe(481) does not seem to have a primary role in CYP2D6-mediated N-dealkylation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11284724      PMCID: PMC1221748          DOI: 10.1042/0264-6021:3550373

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  34 in total

1.  Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors.

Authors:  S Ekins; G Bravi; S Binkley; J S Gillespie; B J Ring; J H Wikel; S A Wrighton
Journal:  Pharmacogenetics       Date:  1999-08

2.  Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6.

Authors:  M J de Groot; M J Ackland; V A Horne; A A Alex; B C Jones
Journal:  J Med Chem       Date:  1999-05-06       Impact factor: 7.446

3.  High-efficiency transformation of yeast by electroporation.

Authors:  D M Becker; L Guarente
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

4.  Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy.

Authors:  C R Jefcoate
Journal:  Methods Enzymol       Date:  1978       Impact factor: 1.600

5.  Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.

Authors:  S V Otton; H K Crewe; M S Lennard; G T Tucker; H F Woods
Journal:  J Pharmacol Exp Ther       Date:  1988-10       Impact factor: 4.030

6.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel; J D Roberts; R A Zakour
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

7.  Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling.

Authors:  T Lightfoot; S W Ellis; J Mahling; M J Ackland; F E Blaney; G J Bijloo; M J De Groot; N P Vermeulen; G M Blackburn; M S Lennard; G T Tucker
Journal:  Xenobiotica       Date:  2000-03       Impact factor: 1.908

8.  The 2.6-A crystal structure of Pseudomonas putida cytochrome P-450.

Authors:  T L Poulos; B C Finzel; I C Gunsalus; G C Wagner; J Kraut
Journal:  J Biol Chem       Date:  1985-12-25       Impact factor: 5.157

9.  Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man.

Authors:  Z R Chen; A A Somogyi; F Bochner
Journal:  Ther Drug Monit       Date:  1990-01       Impact factor: 3.681

10.  Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity.

Authors:  P A Williams; J Cosme; V Sridhar; E F Johnson; D E McRee
Journal:  Mol Cell       Date:  2000-01       Impact factor: 17.970

View more
  8 in total

1.  Tales from the war on error: the art and science of curating QSAR data.

Authors:  Marvin Waldman; Robert Fraczkiewicz; Robert D Clark
Journal:  J Comput Aided Mol Des       Date:  2015-08-20       Impact factor: 3.686

2.  Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism.

Authors:  Rayomand J Unwalla; Jason B Cross; Sumeet Salaniwal; Adam D Shilling; Louis Leung; John Kao; Christine Humblet
Journal:  J Comput Aided Mol Des       Date:  2010-04-02       Impact factor: 3.686

3.  Crystal Structures of Drug-Metabolizing CYPs.

Authors:  D Fernando Estrada; Amit Kumar; Christopher S Campomizzi; Natalie Jay
Journal:  Methods Mol Biol       Date:  2021

Review 4.  Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions.

Authors:  J-D Maréchal; C A Kemp; G C K Roberts; M J I Paine; C R Wolf; M J Sutcliffe
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

Review 5.  Genotype-guided tamoxifen therapy: time to pause for reflection?

Authors:  Timothy L Lash; Ernst A Lien; Henrik Toft Sørensen; Stephen Hamilton-Dutoit
Journal:  Lancet Oncol       Date:  2009-08       Impact factor: 41.316

6.  Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.

Authors:  Jack U Flanagan; Jean-Didier Maréchal; Richard Ward; Carol A Kemp; Lesley A McLaughlin; Michael J Sutcliffe; Gordon C K Roberts; Mark J I Paine; C Roland Wolf
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

7.  Functional characterization of a first avian cytochrome P450 of the CYP2D subfamily (CYP2D49).

Authors:  Hua Cai; Jun Jiang; Qi Yang; Qingmei Chen; Yiqun Deng
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

8.  Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.

Authors:  T L Lash; L Pedersen; D Cronin-Fenton; T P Ahern; C L Rosenberg; K L Lunetta; R A Silliman; S Hamilton-Dutoit; J P Garne; M Ewertz; H T Sørensen
Journal:  Br J Cancer       Date:  2008-07-29       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.